학술논문
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Document Type
Article
Author
Domchek, Susan M ; Postel-Vinay, Sophie; Im, Seock-Ah; Park, Yeon Hee; Delord, Jean-Pierre; Italiano, Antoine; Alexandre, Jerome; You, Benoit; Bastian, Sara; Krebs, Matthew G; Wang, Ding; Waqar, Saiama N; Lanasa, Mark; Rhee, Joon; Gao, Haiyan; Rocher-Ros, Vidalba; Jones, Emma V; Gulati, Sakshi; Coenen-Stass, Anna; Kozarewa, Iwanka; Lai, Zhongwu; Angell, Helen K; Opincar, Laura; Herbolsheimer, Pia; Kaufman, Bella
Source
In The Lancet Oncology September 2020 21(9):1155-1164
Subject
Language
ISSN
1470-2045